An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Clinical trial NCT02041533 · COMPLETED
Trial details
- NCT number
- NCT02041533
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-27
- Primary completion
- 2016-07-01
- Enrollment
- 541
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.